Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
The Compensation Committee of Karyopharm’s Board of Directors granted
In addition, the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 82,000 shares of Karyopharm’s common stock to eight other newly-hired employees, with a grant date of February 28, 2019. Each of these stock options has an exercise price of $4.13 per share, the closing price of Karyopharm’s common stock on the Nasdaq Global Select Market on
Vice President, Investor and Public Relations
857-297-2241 | firstname.lastname@example.org
Source: Karyopharm Therapeutics Inc.